The estimated Net Worth of Daniel K Spiegelman is at least $23.7 Milion dollars as of 3 June 2024. Mr. Spiegelman owns over 7,576 units of Myriad Genetics stock worth over $865,059 and over the last 18 years he sold MYGN stock worth over $22,789,343. In addition, he makes $0 as Independent Director at Myriad Genetics.
Daniel has made over 40 trades of the Myriad Genetics stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 7,576 units of MYGN stock worth $167,051 on 3 June 2024.
The largest trade he's ever made was selling 35,000 units of Myriad Genetics stock on 28 February 2017 worth over $3,292,450. On average, Daniel trades about 4,010 units every 44 days since 2006. As of 3 June 2024 he still owns at least 32,917 units of Myriad Genetics stock.
You can see the complete history of Mr. Spiegelman stock trades at the bottom of the page.
Daniel Keith Spiegelman serves as Independent Director of the Company. Mr. Spiegelman has served as a Chief Financial Officer in several diversified biotechnology companies spanning 30 years. He was most recently Executive Vice President and Chief Financial Officer of BioMarin Pharmaceuticals, Inc., a pharmaceutical company focused on development of first-in-class and best-in-class therapeutics for rare genetic diseases. Having retired from that position after eight years, Dan now serves on the board of Tizona Therapeutics, Inc., a private pharmaceutical company, and has previously served on a number of public and private biotech company boards.
Daniel Spiegelman is 61, he's been the Independent Director of Myriad Genetics since 2020. There are 8 older and 16 younger executives at Myriad Genetics. The oldest executive at Myriad Genetics, Inc. is Walter Gilbert, 87, who is the Independent Vice Chairman of the Board.
Daniel's mailing address filed with the SEC is C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, SUITE 310, HIGH POINT, NC, 27265.
Over the last 22 years, insiders at Myriad Genetics have traded over $51,783,466 worth of Myriad Genetics stock and bought 61,160 units worth $1,252,955 . The most active insiders traders include Jerry S Lanchbury, Peter D Meldrum oraz Arthur H Jr Hayes. On average, Myriad Genetics executives and independent directors trade stock every 18 days with the average trade being worth of $563,312. The most recent stock trade was executed by Heinrich Dreismann on 9 September 2024, trading 10,000 units of MYGN stock currently worth $270,500.
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.
Myriad Genetics executives and other stock owners filed with the SEC include: